---
title: "HuaYuan Securities: AKESO HARMONi data further updated, maintaining a \"Buy\" rating"
description: "Huayuan Securities maintains a \"Buy\" rating on AKESO, expecting operating revenues of 3.419 billion, 5.598 billion, and 8.577 billion yuan for 2025-2027, respectively. The company achieved revenue of "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257024413.md"
published_at: "2025-09-12T03:53:02.000Z"
---

# HuaYuan Securities: AKESO HARMONi data further updated, maintaining a "Buy" rating

> Huayuan Securities maintains a "Buy" rating on AKESO, expecting operating revenues of 3.419 billion, 5.598 billion, and 8.577 billion yuan for 2025-2027, respectively. The company achieved revenue of 1.412 billion yuan in the first half of 2025, a year-on-year increase of 37.75%, with a net profit attributable to the parent company of -570 million yuan. The updated overseas data for the monoclonal antibody Yosprala HARMONi shows further improvement in overall survival (OS), with steady growth in commercialization. Subsequent product approvals are expected to bring incremental performance. The reasonable equity value is HKD 187.5 billion

According to the Zhitong Finance APP, Huayuan Securities released a research report stating that it maintains a "Buy" rating for AKESO (09926), expecting the company's operating revenue for 2025-2027 to be 3.419 billion, 5.598 billion, and 8.577 billion yuan respectively. Using the DCF method, assuming a perpetual growth rate of 3% and a WACC of 7.06%, the company's reasonable equity value is HKD 187.5 billion (with an exchange rate of 1 RMB = 1.07 HKD). Given the company's outstanding innovation pipeline and strong commercialization, the clarity of overseas clinical certainty is gradually improving.

AKESO released its 2025 semi-annual report, achieving revenue of 1.412 billion yuan in H1 2025, a year-on-year increase of 37.75%, with a net profit attributable to the parent of -570 million yuan; R&D expenses were 731 million yuan, a year-on-year increase of 23.06%, sales expenses were 670 million yuan, a year-on-year increase of 29.84%, and management expenses were 134 million yuan, a year-on-year increase of 34.00%. In addition, AKESO announced overseas data for Ivosidenib at the 2025 WCLC conference, showing further improvement in OS, with an OSHR of 0.78, and an OSHR of 0.70 in the North American population, which is even more prominent.

Commercialization is steadily growing, with the performance growth driven by the volume increase of Ivosidenib and Cadonilimab. Benefiting from the rapid volume increase of the two core bispecific antibodies, Cadonilimab and Ivosidenib, after entering medical insurance, the company achieved revenue of 1.412 billion yuan in H1 2025, a year-on-year increase of 37.75%. In terms of product sales revenue, the sales revenue was 1.401 billion yuan, a year-on-year increase of 49.20%, indicating smooth commercialization progress. With subsequent product approvals and new indications, the company continues to make efforts in oncology, autoimmune diseases, metabolism, and other fields, which is expected to bring sufficient performance increments.

The WCLC conference updated OS data for Ivosidenib, showing more significant benefits for the North American population. On September 7, 2025, local time, AKESO's independently developed world-first PD-1/VEGF bispecific antibody Ivosidenib's overseas partner Summit Therapeutics released the updated data of the first global multicenter Phase III clinical HARMONi study at the World Lung Cancer Conference (WCLC 2025): 1) The OS of the HARMONi study further improved, HR=0.78 (P=0.0332), showing a significant improvement trend compared to the previous analysis results in May; 2) The OSHR for the North American population is 0.70; 3) The HARMONi study has achieved clinically meaningful and statistically significant PFS results; in the HARMONi study, the clinical research endpoints including OS and PFS for Western and Asian patients were highly consistent, and also highly consistent with the clinical research data of HARMONi-A.

The firm believes that as the follow-up time extends, the survival benefit trend of Ivosidenib is developing positively, adding strong leverage for the successful FDA approval of Ivosidenib. Currently, the ongoing clinical trials for Ivosidenib include: 1) Lung cancer, first-line NSCLC, first-line sq-NSCLC, NSCLC progressing after EGFR-TKI treatment, first-line PD-L1 positive NSCLC, first-line PD-L1 high expression NSCLC, etc.; 2) Others, first-line biliary cancer, first-line PD-L1 positive head and neck squamous cell carcinoma, first-line TNBC, first-line pancreatic cancer, etc Pay attention to the follow-up progress of the expansion of indications for Ivosidenib

### Related Stocks

- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 康方生物的 Ivonescimab 在 HARMONi-A 三期非小細胞肺癌試驗中展現了顯著的生存優勢 | 康方生物（Akeso Inc.）宣佈其雙特異性抗體 ivonescimab 獲得中國國家藥品監督管理局的重大標籤更新。該更新基於 HARMONi-A III 期臨牀試驗，顯示在接受 EGFR-TKI 治療後的晚期非鱗狀非小細胞肺癌（nsq- | [Link](https://longbridge.com/en/news/271728127.md) |
| 康方生物報告 Cadonilimab 在一線 PD-L1 低表達胃癌研究中表現優於 PD-1 抑制劑 | 康方生物報告稱，卡多利單抗聯合化療在一項針對 PD-L1 CPS  | [Link](https://longbridge.com/en/news/272494568.md) |
| 菲參議員登中業島 籲聯合抗中國南海主權聲索 | 菲律賓參議員洪迪薇近日登上中業島，呼籲加強與他國的防禦關係，持續反抗中國在南海的主權主張。她強調菲律賓人不應放棄「西菲律賓海」的任何部分，並希望與更多國家發展安全與防衞關係。洪迪薇還提到，菲律賓應關注台海衝突的可能性，並表示將為中業島提供基 | [Link](https://longbridge.com/en/news/276518735.md) |
| 川普宣佈即起調高全球關税至 15% 回應最高法院裁決 | 美國總統川普宣佈將進口至美國的全球性關税從 10% 提高至 15%，即刻生效。此舉是對最高法院推翻他先前廣泛關税措施的回應。川普在社交平台上表示，經過對最高法院裁決的檢視，政府決定將關税調升至法律允許的 15% 水平。 | [Link](https://longbridge.com/en/news/276518727.md) |
| 中國白銀集團 (0815) 折讓 18% 配股籌 4.6 億 | 中國白銀集團宣佈將向 6 名認購人發行 9.1 億股認購股份，折讓約 17.74%，每股認購價為 0.51 元，籌集資金總額為 4.641 億元。所得款項將用於日喀則礦的資本開支、進一步融資及一般營運資金。 | [Link](https://longbridge.com/en/news/276432450.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
